A novel role of CRTC2 in promoting nonalcoholic fatty liver disease

Abstract

Objective Diet-induced obesity is often associated with nonalcoholic fatty liver disease (NAFLD), which instigates severe metabolic disorders, including cirrhosis, hepatocellular carcinoma, and type 2 diabetes. We have shown that hepatic depletion of CREB regulated transcription co-activator (CRTC) 2 protects mice from the progression of diet-induced fatty liver phenotype, although the exact mechanism by which CRTC2 modulates this process is elusive to date. Here, we investigated the role of hepatic CRTC2 in the instigation of NAFLD in mammals. Methods Crtc2 liver-specific knockout ( Crtc2 LKO) mice and Crtc2 flox/flox ( Crtc2 f/f) mice were fed a high fat diet (HFD) for 7–8 weeks. Body weight, liver weight, hepatic lipid contents, and plasma triacylglycerol (TG) levels were determined. Western blot analysis was performed to determine Sirtuin (SIRT) 1, tuberous sclerosis complex (TSC) 2, and mammalian target of rapamycin complex (mTORC) 1 activity in the liver. Effects of Crtc2 depletion on lipogenesis was determined by measuring lipogenic gene expression (western blot analysis and qRT-PCR) in the liver as well as Oil red O staining in hepatocytes. Effects of miR-34a on mTORC1 activity and hepatic lipid accumulation was assessed by AAV-miR-34a virus in mice and Ad-miR-34a virus and Ad-anti-miR-34a virus in hepatocytes. Autophagic flux was assessed by western blot analysis after leupeptin injection in mice and bafilomycin treatment in hepatocytes. Lipophagy was assessed by transmission electron microscopy and confocal microscopy. Expression of CRTC2 and p-S6K1 in livers of human NAFLD patients was assessed by immunohistochemistry. Results We found that expression of CRTC2 in the liver is highly induced upon HFD-feeding in mice. Hepatic depletion of Crtc2 ameliorated HFD-induced fatty liver disease phenotypes, with a pronounced inhibition of the mTORC1 pathway in the liver. Mechanistically, we found that expression of TSC2, a potent mTORC1 inhibitor, was enhanced in Crtc2 LKO mice due to the decreased expression of miR-34a and the subsequent increase in SIRT1-mediated deacetylation processes. We showed that ectopic expression of miR-34a led to the induction of mTORC1 pathway, leading to the hepatic lipid accumulation in part by limiting lipophagy and enhanced lipogenesis. Finally, we found a strong association of CRTC2, miR-34a and mTORC1 activity in the NAFLD patients in humans, demonstrating a conservation of signaling pathways among species. Conclusions These data collectively suggest that diet-induced activation of CRTC2 instigates the progression of NAFLD by activating miR-34a-mediated lipid accumulation in the liver via the simultaneous induction of lipogenesis and inhibition of lipid catabolism. Therapeutic approach to specifically...

Targeting pancreatic beta cell death in type 2 diabetes by polyphenols

“…Regarding in vitro studies, resveratrol inhibits mTORC1 signaling pathway by the modulation of the acetylation status of TSC2 (102). Very recently this mechanism has been corroborated in vivo, avoiding lipid accumulation in the liver combating obesity and complications of diabetes (103). Autophagy promotes b-cell survival by enabling adaptive responses to alleviate ER stress, mitochondrial dysfunction and oxidative stress.…”

Obesity-induced miR-802 directly targets AMPK and promotes nonalcoholic steatohepatitis in mice

“…Further, miR-802 in obesity impairs glucose regulation by targeting HNF1β [ 10 ] and inhibits insulin production by targeting NeuroD [ 11 ]. The mechanisms for aberrant expression of miRs in obesity are generally understudied, but aberrant activation of the gene-regulatory proteins, CRTC2 and FOXO1, was shown to increase transcription of hepatic miR-34a and pancreatic miR-802, respectively [ [11] , [12] , [13] , [14] ]. Further, defective nuclear receptor FXR-SHP function increased hepatic expression of miR-34a and miR-802 in obesity [ 4 , 15 ].…”

Hypomethylation-enhanced CRTC2 expression drives malignant phenotypes and primary resistance to immunotherapy in hepatocellular carcinoma

“…As the main coactivator of CREB, CRTC2 controls the transcriptional activity of hepatic gluconeogenesis-related genes. 24 , 25 , 26 Recently, numerous studies have explored the potential role of CRTC2 in malignancies. 27 , 28 , 29 , 30 In this study, we showed that increased CRTC2 expression predicts poor clinical outcomes in patients with HCC.…”

“… 23 , 24 , 25 CRTC2 hepatic depletion effectively ameliorates nonalcoholic steatohepatitis progression by reducing lipid accumulation. 26 Recently, numerous studies have explored the potential role of CRTC2 in malignancies, including lymphoma, lung cancer, prostate cancer, and colorectal cancer. 27 , 28 , 29 , 30 For example, when phosphorylated at Ser238, CRTC2 promotes colorectal cancer progression.…”